FLGT vs. GTH, FTRE, VCYT, VRDN, CDNA, CSTL, CELC, SERA, BDSX, and BNR
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Genetron (GTH), Fortrea (FTRE), Veracyte (VCYT), Viridian Therapeutics (VRDN), CareDx (CDNA), Castle Biosciences (CSTL), Celcuity (CELC), Sera Prognostics (SERA), Biodesix (BDSX), and Burning Rock Biotech (BNR).
Genetron (NASDAQ:GTH) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
Fulgent Genetics has a consensus price target of $30.00, indicating a potential upside of 45.28%. Given Genetron's higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Genetron.
Genetron has higher earnings, but lower revenue than Fulgent Genetics.
10.7% of Genetron shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Genetron has a net margin of 0.00% compared to Genetron's net margin of -57.72%. Fulgent Genetics' return on equity of 0.00% beat Genetron's return on equity.
Genetron has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.
Fulgent Genetics received 242 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 60.70% of users gave Fulgent Genetics an outperform vote while only 33.33% of users gave Genetron an outperform vote.
In the previous week, Fulgent Genetics had 2 more articles in the media than Genetron. MarketBeat recorded 2 mentions for Fulgent Genetics and 0 mentions for Genetron. Genetron's average media sentiment score of 1.40 beat Fulgent Genetics' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the news media.
Summary
Fulgent Genetics beats Genetron on 10 of the 14 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
